Skip to main content
Retour
GYRE logo

Gyre Therapeutics, Inc.

Qualité des données : 100%
GYRE
NASDAQ Healthcare Biotechnology
6,94 €
▼ 0,10 € (-1,42%)
Cap. Boursière : 630,78M
Fourchette du Jour
6,91 € 7,24 €
Fourchette 52 Semaines
6,11 € 11,78 €
Volume
115 642
Moyenne 50J / 200J
7,92 € / 7,75 €
Clôture Précédente
7,04 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 125,5 0,3
P/B 6,0 2,9
ROE % 5,9 3,7
Net Margin % 4,3 3,8
Rev Growth 5Y % 99,7 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
16,00 € +130.5%
BPA Prévisionnel
-0,32 €
CA Est.
140 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 0,25 €
0,21 € – 0,31 €
310 M 1
FY2029 0,11 €
0,09 € – 0,14 €
270 M 1
FY2028 1,71 €
1,42 € – 2,12 €
440 M 1

Points Clés

Revenue grew 99,65% annually over 5 years — strong growth
Earnings declined -58,40% over the past year
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -180 000,0
P/E of 125,48 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 89,41%

Croissance

Revenue Growth (5Y)
99,65%
Revenue (1Y)10,24%
Earnings (1Y)-58,40%
FCF Growth (3Y)N/A

Qualité

Return on Equity
5,94%
ROIC8,05%
Net Margin4,31%
Op. Margin9,85%

Sécurité

Debt / Equity
0,01
Current Ratio5,60
Interest Coverage0,00

Valorisation

P/E Ratio
125,48
P/B Ratio5,95
EV/EBITDA51,77
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,24% Revenue Growth (3Y) 1,37%
Earnings Growth (1Y) -58,40% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 99,65% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 116,59M Net Income (TTM) 5,03M
ROE 5,94% ROA 3,03%
Gross Margin 95,35% Operating Margin 9,85%
Net Margin 4,31% Free Cash Flow (TTM) -180 000,0
ROIC 8,05% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 5,60
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 125,48 P/B Ratio 5,95
P/S Ratio 5,41 PEG Ratio -2,10
EV/EBITDA 51,77 Dividend Yield 0,00%
Market Cap 630,78M Enterprise Value 594,65M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 116,59M 105,76M 113,45M 102,29M 7,34M
Net Income 5,03M 12,09M -92,93M 2,30M -87,93M
EPS (Diluted) 0,02 0,05 -1,41 0,03 -2,87
Gross Profit 111,17M 101,87M 108,81M 97,50M -332 000,0
Operating Income 11,49M 16,16M -67,23M 9,20M -83,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 166,13M 125,41M 116,54M 84,75M 55,66M
Total Liabilities 23,85M 27,00M 102,59M 12,54M 14,57M
Shareholders' Equity 106,03M 63,32M -15,83M 42,52M 41,09M
Total Debt 939 000,0 1,60M 409 000,0 613 000,0 2,39M
Cash & Equivalents 37,07M 11,81M 33,51M 25,18M 44,35M
Current Assets 102,37M 64,79M 57,22M 49,65M 51,48M
Current Liabilities 18,29M 19,52M 20,05M 12,24M 14,17M